Instil Bio announced the resumption of its Phase 1 clinical trial of ITIL-306 for the treatment of non-small cell lung cancer, ovarian cancer, and renal cell carcinoma. With the resumption of the ITIL-306 Phase 1 study, the Company expects to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after the implementation of additional quality safeguards designed to further protect the manufacturing process from potential contaminants.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TIL:
- Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
- Instil Bio price target lowered to $5 from $14 at Baird
- Instil Bio discontinues ITIL-168 clinical programs
- Instil Bio prioritizes CoStAR-TIL program, reduces headcount by 60%
- Instil Bio treatment of stage IB2 to IV cervical cancer granted orphan status